Pfizer sues Johnson & Johnson for alleged monopolistic behaviour
In a move the company is touting as an attempt to get lower-cost biosimilar medicines into the hands of patients, Pfizer has sued Johnson & Johnson for alleged anticompetitive behaviour in the growing biologics market.
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10